Applied BioClinical Inc.

Irvine, CA, United States

Applied BioClinical Inc.

Irvine, CA, United States
Time filter
Source Type

Nemzer B.V.,FutureCeuticals Inc. | Rodriguez L.C.,NutraClinical Inc. | Hammond L.,NutraClinical Inc. | Disilvestro R.,Ohio State University | And 2 more authors.
Nutrition Journal | Year: 2011

Background: Measuring the effects of the acute intake of natural products on human biomarker concentrations, such as those related to oxidation and inflammation, can be an advantageous strategy for early clinical research on an ingredient or product. Methods. 31 total healthy subjects were randomized in a double-blinded, placebo-controlled, acute pilot study with post-hoc subgroup analysis on 20 of the subjects. The study examined the effects of a single dose of a polyphenol-rich beverage (PRB), commercially marketed as "SoZo ", on serum anti-inflammatory and antioxidant markers. In addition, phytochemical analyses of PRB, and in vitro antioxidant capacity were also performed. Results: At 1 hour post-intake, serum values for 8-iso-PGF2-alpha and advanced oxidation protein products decreased significantly by 40% and 39%, respectively. Additionally, there was a trend toward decreased C-reactive protein, and increased nitric oxide levels. Both placebo and PRB treatment resulted in statistically significant increases in hydroxyl radical antioxidant capacity (HORAC) compared to baseline; PRB showed a higher percent change (55-75% versus 23-74% in placebo group), but the two groups did not differ significantly from each other. Conclusions: PRB produced statistically significant changes in several blood biomarkers related to antioxidant/anti-inflammatory effects. Future studies are justified to verify results and test for cumulative effects of repeated intakes of PRB. The study demonstrates the potential utility of acute biomarker measurements for evaluating antioxidant/anti-inflammatory effects of natural products. © 2011 Nemzer et al; licensee BioMed Central Ltd.

Reyes-Izquierdo T.,Applied BioClinical Inc. | Nemzer B.,FutureCeuticals Inc. | Shu C.,Applied BioClinical Inc. | Huynh L.,Applied BioClinical Inc. | And 3 more authors.
British Journal of Nutrition | Year: 2013

The present single-dose study was performed to assess the effect of whole coffee fruit concentrate powder (WCFC), green coffee caffeine powder (N677), grape seed extract powder (N31) and green coffee bean extract powder (N625) on blood levels of brain-derived neurotrophic factor (BDNF). Randomly assorted groups of fasted subjects consumed a single, 100 mg dose of each material. Plasma samples were collected at time zero (T 0) and at 30 min intervals afterwards, up to 120 min. A total of two control groups were included: subjects treated with silica dioxide (as placebo) or with no treatment. The collected data revealed that treatments with N31 and N677 increased levels of plasma BDNF by about 31 % under these experimental conditions, whereas treatment with WCFC increased it by 143 % (n 10), compared with baseline. These results indicate that WCFC could be used for modulation of BDNF-dependent health conditions. However, larger clinical studies are needed to support this possibility. © 2013 The Authors.

Wybraniec S.,Cracow University of Technology | Starzak K.,Cracow University of Technology | Skopinska A.,Cracow University of Technology | Nemzer B.,FutureCeuticals Inc. | And 2 more authors.
Journal of Agricultural and Food Chemistry | Year: 2013

A comprehensive nonenzymatic oxidation mechanism in betanin plant pigment as well as its derivatives, 2-decarboxybetanin, 17-decarboxybetanin, 2,17-bidecarboxybetanin, and neobetanin, in the presence of ABTS cation radicals was investigated by LC-DAD-ESI-MS/MS. The main compounds formed during the first step of betanin and 2-decarboxybetanin oxidation are 2-decarboxy-2,3- dehydrobetanin and 2-decarboxyneobetanin, respectively. In contrast to betanin, the reaction mechanism for 2-decarboxybetanin includes more oxidation pathways. Parallel transformation of 2-decarboxybetanin quinone methide produces neoderivatives according to an alternative reaction that omits the presumably more stabile intermediate 2-decarboxy-2,3-dehydrobetanin. The main oxidation product after the first reaction step for both 17-decarboxybetanin and 2,17-bidecarboxybetanin is 2,17-decarboxy-2,3-dehydrobetanin. This product is formed through irreversible decarboxylation of the 17-decarboxybetanin quinone methide or by oxidation of 2,17-bidecarboxybetanin. Oxidation of neobetanin results primarily in a formation of 2-decarboxy-2,3-dehydroneobetanin by a decarboxylative transformation of the formed neobetanin quinone methide. The elucidated reaction scheme will be useful in interpretation of redox activities of betalains in biological tissues and food preparations. © 2013 American Chemical Society.

Ratajczak J.,University of Louisville | Kucia M.,University of Louisville | Mierzejewska K.,University of Louisville | Mierzejewska K.,Pomeranian Medical University | And 7 more authors.
Stem Cells and Development | Year: 2013

CD133+ cells purified from hematopoietic tissues are enriched mostly for hematopoietic stem/progenitor cells, but also contain some endothelial progenitor cells and very small embryonic-like stem cells. CD133+ cells, which are akin to CD34+ cells, are a potential source of stem cells in regenerative medicine. However, the lack of convincing donor-derived chimerism in the damaged organs of patients treated with these cells suggests that the improvement in function involves mechanisms other than a direct contribution to the damaged tissues. We hypothesized that CD133+ cells secrete several paracrine factors that play a major role in the positive effects observed after treatment and tested supernatants derived from these cells for the presence of such factors. We observed that CD133+ cells and CD133+ cell-derived microvesicles (MVs) express mRNAs for several antiapoptotic and proangiopoietic factors, including kit ligand, insulin growth factor-1, vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8. These factors were also detected in a CD133+ cell-derived conditioned medium (CM). More important, the CD133+ cell-derived CM and MVs chemoattracted endothelial cells and display proangiopoietic activity both in vitro and in vivo assays. This observation should be taken into consideration when evaluating clinical outcomes from purified CD133+ cell therapies in regenerative medicine. © 2013, Mary Ann Liebert, Inc.

Reyes-Izquierdo T.,Applied BioClinical Inc. | Hammond L.E.,Applied BioClinical Inc. | Sikorski R.S.,FutureCeuticals Inc. | Nemzer B.,FutureCeuticals Inc. | Pietrzkowski Z.,Applied BioClinical Inc.
Current Topics in Nutraceutical Research | Year: 2011

Human peripheral blood mononuclear cells (PBMC) were used as a biological model to measure intracellular ATP (iATP) reactive oxygen species (ROS), Oxygen Consumption Rate (OCR) and extracellular acidification rate (ECAR), in response to acute ex vivo treatments with HH2o. "HH2o", a fermented, food-based material commercially marketed as "Mitochroma™ has been identified as a potential modulator of iATP, OCR and ROS in these cells. PBMC were exposed to HH2O (0.1, 0.01 and 0.001% w/v) and Carbonyl-cyanide p-trifluoro-methoxyphenyl-hydrazone (FCCP) or Oligomycin, two known modulators of mitochondrial activity were used as controls. Results showed that treatment of the cells with HH2O resulted in increase of iA TP up to 220% and reduction of iADP by up to 40% while iROS levels remained unchanged. At the same time, OCR level was increased up to 24% compared to initial baseline. These results suggest that HH2O acts similarly to uncoupling protein 2 (UCP2) when induced and that it may have potential use in developing health-promoting products. These results support the use of freshly isolated human PBMCs as an experimental ex vivo model to detect the effects of nutraceutical products on dynamic cell metabolites, such as oxygen consumption, ATP, ADP and ROS. Copyright © 2011 by New Century Health Publishers, LLC.

Loading Applied BioClinical Inc. collaborators
Loading Applied BioClinical Inc. collaborators